CN111565744B - 紧密连接蛋白6抗体和治疗癌症的方法 - Google Patents

紧密连接蛋白6抗体和治疗癌症的方法 Download PDF

Info

Publication number
CN111565744B
CN111565744B CN201880073220.3A CN201880073220A CN111565744B CN 111565744 B CN111565744 B CN 111565744B CN 201880073220 A CN201880073220 A CN 201880073220A CN 111565744 B CN111565744 B CN 111565744B
Authority
CN
China
Prior art keywords
antigen binding
seq
binding protein
antibody
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880073220.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN111565744A (zh
Inventor
D·康克林
D·斯拉蒙
N·奥布赖恩
M·帕拉佐洛
E·冯尤伊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California, San Diego
Original Assignee
University of California, San Diego
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California, San Diego filed Critical University of California, San Diego
Priority to CN202410853420.8A priority Critical patent/CN118667021A/zh
Publication of CN111565744A publication Critical patent/CN111565744A/zh
Application granted granted Critical
Publication of CN111565744B publication Critical patent/CN111565744B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
CN201880073220.3A 2017-09-18 2018-09-18 紧密连接蛋白6抗体和治疗癌症的方法 Active CN111565744B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410853420.8A CN118667021A (zh) 2017-09-18 2018-09-18 紧密连接蛋白6抗体和治疗癌症的方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762560143P 2017-09-18 2017-09-18
US62/560,143 2017-09-18
PCT/US2018/051610 WO2019056023A2 (en) 2017-09-18 2018-09-18 ANTIBODIES AGAINST CLAUDIN 6 AND METHODS OF TREATING CANCER

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202410853420.8A Division CN118667021A (zh) 2017-09-18 2018-09-18 紧密连接蛋白6抗体和治疗癌症的方法

Publications (2)

Publication Number Publication Date
CN111565744A CN111565744A (zh) 2020-08-21
CN111565744B true CN111565744B (zh) 2024-12-31

Family

ID=65723110

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201880073220.3A Active CN111565744B (zh) 2017-09-18 2018-09-18 紧密连接蛋白6抗体和治疗癌症的方法
CN202410853420.8A Pending CN118667021A (zh) 2017-09-18 2018-09-18 紧密连接蛋白6抗体和治疗癌症的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202410853420.8A Pending CN118667021A (zh) 2017-09-18 2018-09-18 紧密连接蛋白6抗体和治疗癌症的方法

Country Status (22)

Country Link
US (4) US20200291111A1 (cg-RX-API-DMAC10.html)
EP (2) EP3826667B1 (cg-RX-API-DMAC10.html)
JP (2) JP7599332B2 (cg-RX-API-DMAC10.html)
KR (2) KR102793719B1 (cg-RX-API-DMAC10.html)
CN (2) CN111565744B (cg-RX-API-DMAC10.html)
AU (2) AU2018334434B2 (cg-RX-API-DMAC10.html)
BR (1) BR112020005196A2 (cg-RX-API-DMAC10.html)
CA (1) CA3076207A1 (cg-RX-API-DMAC10.html)
CZ (1) CZ2021138A3 (cg-RX-API-DMAC10.html)
DK (1) DK3826667T3 (cg-RX-API-DMAC10.html)
ES (1) ES2986343T3 (cg-RX-API-DMAC10.html)
FI (1) FI3826667T3 (cg-RX-API-DMAC10.html)
GB (1) GB202103867D0 (cg-RX-API-DMAC10.html)
HU (1) HUE067603T2 (cg-RX-API-DMAC10.html)
IL (2) IL313238A (cg-RX-API-DMAC10.html)
MX (2) MX428953B (cg-RX-API-DMAC10.html)
NO (1) NO20210351A1 (cg-RX-API-DMAC10.html)
PL (1) PL3826667T3 (cg-RX-API-DMAC10.html)
PT (1) PT3826667T (cg-RX-API-DMAC10.html)
SG (1) SG11202002114RA (cg-RX-API-DMAC10.html)
SI (1) SI3826667T1 (cg-RX-API-DMAC10.html)
WO (1) WO2019056023A2 (cg-RX-API-DMAC10.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202002114RA (en) * 2017-09-18 2020-04-29 Univ California Claudin6 antibodies and methods of treating cancer
CA3177215C (en) 2017-09-29 2026-06-09 Daiichi Sankyo Company, Limited Antibody-pyrrolobenzodiazepine derivative conjugate
KR102063341B1 (ko) * 2018-12-31 2020-01-07 다이노나(주) Icam-1에 특이적으로 결합하는 항체 및 그의 용도
CN119708241A (zh) 2019-02-15 2025-03-28 因特格尔莫来库乐有限公司 密封蛋白6抗体及其用途
DK3941946T3 (da) * 2019-03-20 2025-03-24 Univ California Claudin-6-antistoffer og lægemiddelkonjugater
WO2020191344A1 (en) * 2019-03-20 2020-09-24 The Regents Of The University Of California Claudin-6 bispecific antibodies
US11834512B2 (en) 2020-05-04 2023-12-05 The Regents Of The University Of California Inhibiting anti-ENPP1 antibodies
CN112386687B (zh) * 2020-12-09 2021-05-04 爱龄医美国际健康咨询服务(北京)有限公司 一种干细胞外泌体及其在药品和化妆品中的应用
WO2023091512A2 (en) * 2021-11-16 2023-05-25 Allakos, Inc. Antibodies to anti-siglec-9 and multispecific antibodies targeting siglec-7 and siglec-9
AU2023219174A1 (en) * 2022-02-09 2024-08-15 Sera Prognostics, Inc. Shbg and ibp4 antibodies and methods using same
CN120282987A (zh) 2022-11-30 2025-07-08 因特格尔莫来库乐有限公司 包括双特异性型式的针对紧密连接蛋白6的抗体
KR20260015262A (ko) 2023-05-25 2026-02-02 더 리전트 오브 더 유니버시티 오브 캘리포니아 암 치료를 위한 클라우딘-6 접합체의 투여량
JPWO2025075127A1 (cg-RX-API-DMAC10.html) * 2023-10-04 2025-04-10
TW202542202A (zh) * 2024-01-04 2025-11-01 美商翰森生物有限責任公司 抗體、抗原結合片段及其醫療用途
AU2025213885A1 (en) * 2024-02-01 2026-07-16 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anti-cldn6 antibody, antibody-drug conjugate thereof, and medical use thereof
WO2026084392A1 (ko) * 2024-10-14 2026-04-23 에이비엘바이오 주식회사 항-클라우딘6 항체 및 이의 용도
KR102953072B1 (ko) * 2025-08-20 2026-04-16 주식회사 누리사이언스 난소 및 난자의 성숙 및/또는 발달을 위한 조성물 및 이의 용도

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012003956A1 (en) * 2010-07-06 2012-01-12 Ganymed Pharmaceuticals Ag Cancer therapy using cldn6 target-directed antibodies in vivo
CN103748112A (zh) * 2011-05-13 2014-04-23 加尼梅德药物公司 用于治疗表达密蛋白6之癌症的抗体

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4450150A (en) 1973-05-17 1984-05-22 Arthur D. Little, Inc. Biodegradable, implantable drug delivery depots, and method for preparing and using the same
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
DE3587500T2 (de) 1984-12-04 1993-12-16 Lilly Co Eli Tumorbehandlung bei Säugetieren.
WO1999040942A1 (en) 1998-02-10 1999-08-19 Yoshitomi Pharmaceutical Industries, Ltd. Preparations with controlled release
JP2003530297A (ja) 1998-10-16 2003-10-14 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ， リプリゼンテッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ Ｖｉｐアンタゴニストを用いる併用療法
GB2344287A (en) 1998-12-03 2000-06-07 Ferring Bv Controlled release pharmaceutical formulation
WO2001058479A1 (en) 2000-02-08 2001-08-16 The Penn State Research Foundation Immunotherapy using interleukin 13 receptor subunit alpha 2
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
WO2004033036A2 (en) 2002-10-04 2004-04-22 Microchips, Inc. Medical device for controlled drug delivery and cardiac monitoring and/or stimulation
CA2672581A1 (en) * 2006-12-14 2008-06-19 Forerunner Pharma Research Co., Ltd. Anti-claudin 3 monoclonal antibody and treatment and diagnosis of cancer using the same
WO2008130158A1 (en) 2007-04-19 2008-10-30 Dong-A Pharmaceutical. Co., Ltd A biodegradable microsphere composition suitable for the controlled release of glucose controlling peptide and formulation thereof
AU2009203464A1 (en) * 2008-01-11 2009-07-16 Forerunner Pharma Research Co., Ltd. Anti-CLDN6 antibody
WO2015014376A1 (en) * 2013-07-31 2015-02-05 Biontech Ag Diagnosis and therapy of cancer involving cancer stem cells
AU2014346792A1 (en) * 2013-11-06 2016-06-02 Abbvie Stemcentrx Llc Novel anti-claudin antibodies and methods of use
CN106459165B (zh) * 2014-04-01 2021-04-20 拜恩科技细胞&基因治疗有限公司 密封蛋白-6特异性免疫受体和t细胞表位
SG11202002114RA (en) * 2017-09-18 2020-04-29 Univ California Claudin6 antibodies and methods of treating cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012003956A1 (en) * 2010-07-06 2012-01-12 Ganymed Pharmaceuticals Ag Cancer therapy using cldn6 target-directed antibodies in vivo
CN103748112A (zh) * 2011-05-13 2014-04-23 加尼梅德药物公司 用于治疗表达密蛋白6之癌症的抗体

Also Published As

Publication number Publication date
MX2025012685A (es) 2025-11-03
SG11202002114RA (en) 2020-04-29
KR20250050137A (ko) 2025-04-14
IL273196B2 (en) 2024-11-01
JP7599332B2 (ja) 2024-12-13
IL313238A (en) 2024-07-01
AU2018334434A1 (en) 2020-04-02
MX428953B (es) 2025-11-13
IL273196A (en) 2020-04-30
CN118667021A (zh) 2024-09-20
US20250333501A1 (en) 2025-10-30
NO20210351A1 (en) 2021-03-18
EP3826667A2 (en) 2021-06-02
CA3076207A1 (en) 2019-03-21
EP4435009A3 (en) 2025-02-26
KR102793719B1 (ko) 2025-04-08
HUE067603T2 (hu) 2024-10-28
US20220372134A1 (en) 2022-11-24
ES2986343T3 (es) 2024-11-11
CN111565744A (zh) 2020-08-21
SI3826667T1 (sl) 2024-09-30
CZ2021138A3 (cs) 2021-09-15
KR20200070238A (ko) 2020-06-17
US20240400674A1 (en) 2024-12-05
BR112020005196A2 (pt) 2020-09-15
JP2024150445A (ja) 2024-10-23
AU2018334434B2 (en) 2025-01-23
PT3826667T (pt) 2024-08-02
MX2020002921A (es) 2020-09-28
JP2020536507A (ja) 2020-12-17
EP4435009A2 (en) 2024-09-25
EP3826667B1 (en) 2024-04-17
PL3826667T3 (pl) 2024-09-30
IL273196B1 (en) 2024-07-01
WO2019056023A2 (en) 2019-03-21
JP7869831B2 (ja) 2026-06-03
FI3826667T3 (fi) 2024-07-22
AU2025200467A1 (en) 2025-04-10
DK3826667T3 (da) 2024-07-22
WO2019056023A3 (en) 2019-05-16
GB202103867D0 (en) 2021-05-05
EP3826667A4 (en) 2022-07-27
US20200291111A1 (en) 2020-09-17

Similar Documents

Publication Publication Date Title
KR102793719B1 (ko) 클라우딘6 항체 및 암치료방법
JP7856818B2 (ja) クローディン６二重特異性抗体
JP7856817B2 (ja) クローディン６抗体及び薬物複合体
JP7595696B2 (ja) Ｃｄ３抗原結合性断片及びその使用
KR102877478B1 (ko) 유전 물질을 인간 세포 내로 표적화하여 도입하기 위한 향성-변형 재조합 바이러스 벡터 및 이의 용도
CN114181310B (zh) 抗tigit抗体、其药物组合物及用途
KR102339240B1 (ko) 펩타이드 키메라 항원 수용체 t 세포 스위치 및 이의 용도
KR101920946B1 (ko) Ｃｓｆ－1ｒ에 대한 항체
AU634186B2 (en) Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
WO2017071625A1 (zh) 一种抗pd-1单克隆抗体、其药物组合物及其用途
CN111018987B (zh) 一种能与人内皮素受体特异性结合的抗体及其应用
KR20110050541A (ko) 항-ｃｄ５ 항체
KR20150030675A (ko) 항ｂｍｐ９ 항체를 유효 성분으로 하는, 신장성 빈혈, 암성 빈혈 등의 빈혈에 대한 치료제
KR20110084280A (ko) 종양 항원의 생물 활성을 특이적으로 차단하는 항체
US20220411501A1 (en) Anti-cd117 antibodies and methods of use thereof
KR102102239B1 (ko) 유방암을 치료하기 위한 방법
US20230331842A1 (en) Antibodies targeting the b-cell receptor of chronic lymphocytic leukemia and uses thereof
JP2025534367A (ja) 抗ｆｇｆｒ２ｂ抗体及びその使用
CN115626956A (zh) Ctla-4结合分子及其用途
RU2778053C2 (ru) Антитела к lag3
HK40031291A (en) Methods of treating triple negative breast cancer and basal-like breast cancer using inhibitors against kidney associated 1 (kaag1) inhibitor
KR20260022380A (ko) Axl에 특이적으로 결합하는 단일클론 항체 또는 이의 항원 결합 단편 및 그 용도
HK40024246A (en) An antibody that specifically binds to human endothelin receptor and use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TG01 Patent term adjustment

Free format text: NEW EXPIRY DATE: 20380926

TG01 Patent term adjustment